126 related articles for article (PubMed ID: 11595538)
1. Osteosarcoma risk in rats using PTH 1-34.
Barbehenn EK; Lurie P; Wolfe SM
Trends Endocrinol Metab; 2001 Nov; 12(9):383. PubMed ID: 11595538
[No Abstract] [Full Text] [Related]
2. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.
Vahle JL; Sato M; Long GG; Young JK; Francis PC; Engelhardt JA; Westmore MS; Linda Y; Nold JB
Toxicol Pathol; 2002; 30(3):312-21. PubMed ID: 12051548
[TBL] [Abstract][Full Text] [Related]
3. Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma.
Andrews EB; Gilsenan A; Midkiff K; Harris D
Ann Epidemiol; 2016 Nov; 26(11):751-753. PubMed ID: 27645108
[No Abstract] [Full Text] [Related]
4. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).
Jolette J; Attalla B; Varela A; Long GG; Mellal N; Trimm S; Smith SY; Ominsky MS; Hattersley G
Regul Toxicol Pharmacol; 2017 Jun; 86():356-365. PubMed ID: 28389324
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human parathyroid hormone. Preclinical data on rat osteosarcoma were not dismissed.
Kuijpers G; Schneider B; Stadel B; Colman E
BMJ; 2002 May; 324(7347):1218; author reply 1218. PubMed ID: 12016199
[No Abstract] [Full Text] [Related]
6. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats.
Jolette J; Wilker CE; Smith SY; Doyle N; Hardisty JF; Metcalfe AJ; Marriott TB; Fox J; Wells DS
Toxicol Pathol; 2006; 34(7):929-40. PubMed ID: 17178693
[TBL] [Abstract][Full Text] [Related]
7. On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84).
Tashjian AH; Goltzman D
J Bone Miner Res; 2008 Jun; 23(6):803-11. PubMed ID: 18435577
[No Abstract] [Full Text] [Related]
8. The activation of cAMP-dependent protein kinase is directly linked to homologous desensitization by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells.
Sugimoto T; Kano J; Fukase M; Fujita T
Horm Metab Res; 1992 Jul; 24(7):347-8. PubMed ID: 1325405
[No Abstract] [Full Text] [Related]
9. [Fluorides and osteosarcoma: human experience is reassuring but need a careful interpretation].
Valiquette L; Kosatsky T; Armstrong B
Can J Public Health; 1992; 83(1):75-7. PubMed ID: 1571889
[No Abstract] [Full Text] [Related]
10. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.
Andrews EB; Gilsenan AW; Midkiff K; Sherrill B; Wu Y; Mann BH; Masica D
J Bone Miner Res; 2012 Dec; 27(12):2429-37. PubMed ID: 22991313
[TBL] [Abstract][Full Text] [Related]
11. PTH analogues and osteoporotic fractures.
Verhaar HJ; Lems WF
Expert Opin Biol Ther; 2010 Sep; 10(9):1387-94. PubMed ID: 20629581
[TBL] [Abstract][Full Text] [Related]
12. The participation of the activation of cAMP-dependent protein kinase in cytosolic acidification by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells.
Sugimoto T; Kano J; Fukase M; Fujita T
Horm Metab Res; 1992 Sep; 24(9):448-9. PubMed ID: 1427618
[No Abstract] [Full Text] [Related]
13. Osteosarcoma and teriparatide?
Harper KD; Krege JH; Marcus R; Mitlak BH
J Bone Miner Res; 2007 Feb; 22(2):334. PubMed ID: 17129179
[No Abstract] [Full Text] [Related]
14. [Osteosarcoma induced in rabbits by 4-nitroquinoline-1-oxide].
Huang CD; Li ZS; Liu ZJ
Zhonghua Wai Ke Za Zhi; 1987 Dec; 25(12):691-2, 733. PubMed ID: 3133181
[No Abstract] [Full Text] [Related]
15. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
[TBL] [Abstract][Full Text] [Related]
16. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)).
Watanabe A; Yoneyama S; Nakajima M; Sato N; Takao-Kawabata R; Isogai Y; Sakurai-Tanikawa A; Higuchi K; Shimoi A; Yamatoya H; Yoshida K; Kohira T
J Toxicol Sci; 2012; 37(3):617-29. PubMed ID: 22688001
[TBL] [Abstract][Full Text] [Related]
17. Caution needed in fluoride and osteosarcoma study.
Douglass CW; Joshipura K
Cancer Causes Control; 2006 May; 17(4):481-2. PubMed ID: 16596300
[No Abstract] [Full Text] [Related]
18. Second messenger signaling in the regulation of cytosolic pH and DNA synthesis by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells: role of Na+/H+ exchange.
Sugimoto T; Kano J; Fukase M; Fujita T
J Cell Physiol; 1992 Jul; 152(1):28-34. PubMed ID: 1320038
[TBL] [Abstract][Full Text] [Related]
19. [Is it possible to utilize experimental osteosarcoma in clinical practice?].
Kalman E
Bratisl Lek Listy; 1970 Oct; 54(4):401-6. PubMed ID: 5273737
[No Abstract] [Full Text] [Related]
20. National Toxicology program report on fluoride and cancer.
Gabler WL
J Oreg Dent Assoc; 1991; 60(4):32-3. PubMed ID: 1856781
[No Abstract] [Full Text] [Related]
[Next] [New Search]
